Moreover, compared with the control group, volasertib can increase the signal of M1 macrophages marker iNOS in the tumor region, which suggested that PLK1 inhibition could increase the M1 macrophages infiltration to glioma TIM (Figure 9M). Here, PLK1 is linked to central nervous system cancer.